| Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro SM Fred, S Kuivanen, H Ugurlu, PC Casarotto, L Levanov, K Saksela, ... Frontiers in Pharmacology 12, 755600, 2022 | 62 | 2022 |
| A generic, scalable, and rapid time-resolved Förster resonance energy transfer-based assay for antigen detection—SARS-CoV-2 as a proof of concept J Rusanen, L Kareinen, L Szirovicza, H Uğurlu, L Levanov, ... MBio 12 (3), 10.1128/mbio. 00902-21, 2021 | 46 | 2021 |
| SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study M Knip, A Parviainen, M Turtinen, A But, T Härkönen, J Hepojoki, ... The lancet Diabetes & endocrinology 11 (4), 251-260, 2023 | 34 | 2023 |
| Tyrosine phosphorylation directs TACE into extracellular vesicles via unconventional secretion Z Zhao, T Kesti, H Uğurlu, AS Baur, R Fagerlund, K Saksela Traffic 20 (3), 202-212, 2019 | 13 | 2019 |
| Intranasal trimeric sherpabody inhibits SARS-CoV-2 including recent immunoevasive Omicron subvariants AR Mäkelä, H Uğurlu, L Hannula, R Kant, P Salminen, R Fagerlund, ... Nature Communications 14 (1), 1637, 2023 | 11 | 2023 |
| Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models TL Freitag, R Fagerlund, NL Karam, VM Leppänen, H Ugurlu, R Kant, ... Vaccine 41 (20), 3233-3246, 2023 | 8 | 2023 |
| Double-blinded, randomised, placebo-controlled trial of convalescent plasma for COVID-19: Analyses by neutralising antibodies homologous to recipients’ variants T Khawaja, M Kajova, I Levonen, JP Pietilä, H Välimaa, J Paajanen, ... Infectious Diseases 56 (6), 423-433, 2024 | 4 | 2024 |
| MC159 of molluscum contagiosum virus suppresses autophagy by recruiting cellular SH3BP4 via an SH3 domain-mediated interaction C Schmotz, H Uğurlu, S Vilen, S Shrestha, R Fagerlund, K Saksela Journal of Virology 93 (10), 10.1128/jvi. 01613-18, 2019 | 4 | 2019 |
| Structure of SNX9 SH3 in complex with a viral ligand reveals the molecular basis of its unique specificity for alanine-containing class I SH3 motifs H Tossavainen, H Uğurlu, M Karjalainen, M Hellman, L Antenucci, ... Structure 30 (6), 828-839. e6, 2022 | 1 | 2022 |
| Intranasal inhibitor blocks omicron and other variants of SARS-CoV-2 AR Mäkelä, H Uğurlu, L Hannula, P Salminen, R Kant, R Fagerlund, ... | 1 | 2021 |
| Altered spike dynamics drives immune evasion of SARS-CoV-2 K Saksela, H Ugurlu, P Salminen, M Yuan, R Fagerlund, A Mäkelä, ... | | 2024 |
